FDA Extends Tinlarebant Review to May 2027

Belite Bio disclosed November 20 that FDA extended the review goal for tinlarebant in Stargardt disease type 1 by three months, from February 12 to May 12, 2027. The extension changes the regulatory clock;…

Belite Bio disclosed November 20 that FDA extended the review goal for tinlarebant in Stargardt disease type 1 by three months, from February 12 to May 12, 2027. The extension changes the regulatory clock;…

Merck reported November 20 that global Phase 3 TroFuse-015 met its primary overall-survival endpoint in third-line or later advanced gastroesophageal adenocarcinoma. The trial did not meet blinded-review progression-free survival, making the topline positive for…

A Nature Medicine study published online November 19 characterized immune effector cell-associated enterocolitis after BCMA CAR T, predominantly cilta-cel. This is an important safety signal in myeloma, not a new estimate of product-wide mortality.

Celldex reported November 19 that Phase 2 barzolvolimab did not significantly improve peak itch versus placebo in moderate-to-severe atopic dermatitis. The result challenges mast-cell depletion as a sufficient intervention in this population, while leaving…

China approved oral Syk inhibitor sovleplenib for previously treated chronic primary immune thrombocytopenia and corticosteroid-insufficient warm autoimmune hemolytic anemia on November 19. Two distinct blood-disease labels create a meaningful domestic regulatory validation; foreign approval…

FDA approved cemdisiran, Livsayis, for adults with anti-AChR-positive generalized myasthenia gravis on November 18. The approval adds a quarterly subcutaneous C5-silencing option, with a boxed warning and REMS for meningococcal infection.

Zelgen disclosed that an independent monitoring committee found its randomized Chinese pivotal interim analysis of alveltamig, ZG006, met the prespecified primary efficacy endpoint in third-line or later advanced small-cell lung cancer. The filing does…

FDA approved venglustat, Infilbray, on November 18 for neurological symptoms of Gaucher type 3 in adults and children weighing at least 15 kg. This is the first FDA-approved therapy for that neurological manifestation, with…

Merck discontinued the full BELLWAVE nemtabrutinib program for CLL, SLL and other hematologic cancers after an external data monitoring committee judged that benefit may not outweigh risk in Phase 3 BELLWAVE-011. Merck reviewed the…

FDA approved intrathecal adrabetadex (Lembaz) for patients with Niemann–Pick disease type C whose neurological symptoms began before age six and who weigh at least 7 kg. FDA described a 55% lower death risk versus…